Cellectis has been granted a patent for Chimeric Antigen Receptors (CAR) using a 5T4 monoclonal antibody for specific immunity against 5T4 positive cells. The engineered immune cells are designed for treating lymphomas, leukemia, and solid tumors like colon, stomach, and ovarian tumors. GlobalData’s report on Cellectis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cellectis, CAR-T cell based therapies was a key innovation area identified from patents. Cellectis's grant share as of May 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Chimeric antigen receptor (car) for 5t4 positive cells
A recently granted patent (Publication Number: US11987639B2) discloses a polynucleotide encoding a 5T4 (NTRKR1) specific chimeric antigen receptor (CAR) designed for engineered immune cells. The CAR includes an extracellular ligand binding-domain with specific variable heavy and light chains, a CD8a hinge, and a CD8a transmembrane domain. The cytoplasmic domain comprises a CD3 zeta signaling domain and a co-stimulatory domain from 4-1 BB. The engineered immune cell expressing this CAR is derived from various T-lymphocytes and is engineered to suppress the expression of a T-cell receptor (TCR). Additionally, the cell can be mutated to resist immune suppressive or chemotherapy drugs.
Furthermore, the engineered immune cell's components, such as the hinge, transmembrane domain, signaling domain, and co-stimulatory domain, have specific amino acid sequences detailed in the patent claims. The extracellular ligand binding-domain and the 5T4 specific CAR also have defined amino acid sequences. The patent emphasizes the precise design and composition of the engineered immune cell expressing the 5T4 specific CAR, highlighting the importance of these specific sequences for its functionality and effectiveness in targeting 5T4 (NTRKR1) antigens on the cell surface membrane. This patent provides a detailed blueprint for creating engineered immune cells with enhanced capabilities for targeted therapy.
To know more about GlobalData’s detailed insights on Cellectis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
